KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  The Oncologist

• Publication date

  2011-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1634/theoncologist.2011-0011PMID 21737577PMCID PMC3228147
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

  2023cited by this paper
• Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

  2010cited by this paper
• Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status.

  2010cited by this paper
• Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

  2010cited by this paper
• Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

  2009cited by this paper
• Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC).

  2009cited by this paper
• Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC).

  2009cited by this paper
• Association of BRAF mutations and EGFR Intron-1 L/L genotype with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients.

  2009cited by this paper
• Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.

  2009cited by this paper
• Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

  2009cited by this paper
• Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

  2008cited by this paper
• Abstracts of the ESMO International Symposium: 10th World Congress on Gastrointestinal Cancer. June 25-28, 2008. Barcelona, Spain.

  2008cited by this paper
• Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

  2008cited by this paper
• Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

  2008cited by this paper
• KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience

  2008cited by this paper
• KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience

  2008cited by this paper
• K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

  2008cited by this paper
• Cancer clinical trials : proactive strategies

  2007cited by this paper
• Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study

  2007cited by this paper
• 7LB Analysis of KRAS mutations in patients with metastatic colorectal cancer receiving panitumumab monotherapy

  2007cited by this paper
• Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial

  2007cited by this paper
• A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.

  2007cited by this paper
• The role of cooperative groups in cancer clinical trials.

  2007cited by this paper
• KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

  2006cited by this paper
• Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.

  2005cited by this paper
• Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.

  1993cited by this paper

• Ethical aspects in managing patients diagnosed with digestive cancers; a review of literature

  2019cites this paper
• EZH2 expression is a prognostic biomarker in patients with colorectal cancer treated with anti-EGFR therapeutics

  2017cites this paper
• Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells

  2016cites this paper
• Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer

  2015cites this paper
• The challenge to optimize medical therapy for advanced colorectal cancer.

  2014cites this paper
• Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer

  2014cites this paper
• Metallothionein Lower Under-Expression in Benign Tumors than That in Malignant Tumors: Systematic Review Article and Meta-Analysis

  2014cites this paper
• Oncologists' response to new data regarding the use of epidermal growth factor receptor inhibitors in colorectal cancer.

  2014cites this paper
• Oncologists' attitudes toward KRAS testing: a multisite study

  2013cites this paper
• The role of personalized medicine in metastatic colorectal cancer: an evolving landscape

  2013cites this paper
• Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung Cancer: SWOG S0536

  2013cites this paper
• HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients

  2013influential citation
• Beyond exon 2--the developing story of RAS mutations in colorectal cancer.

  2013cites this paper
• Pharmacogenomics and personalized medicine: wicked problems, ragged edges and ethical precipices.

  2012cites this paper
• Optimal Treatment Strategies for Localized and Advanced Microsatellite Instability–High Colorectal Cancer

  2012cites this paper
• Publication of tumor marker research results: the necessity for complete and transparent reporting.

  2012cites this paper
• Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer

  2011cites this paper